The p chain (CD18, 95 Kd) can associate with different a chains with a molecular mass of 175 Kd, 165 Kd, or 150 Kd, forming a structure designated CDlla/LFA-1, CDllb/ CR3/Mac-l/Mo-l/OKM-l, and CDllc/p150,95, respect i~e l y .~ CD1 l a is expressed on most leukocytes, whereas expression of CD54 varies on these cells, depending on the state of activation? CDlla-CD18 and CD54 establish a weak association between CTLs and potential target cells, preceding antigenic recogniti~n.~ If, subsequently, the T-cell receptor recognizes its ligand, the CD1 l a molecule is phosphorylated, tightening the bond with CD54, which enables the T-cell to perform its cytolytic acti0n.8.~ Some B-cell neoplasms lack expression of CD1 la1°-12 and, although no correlation was found between the expression of CDlla and the clinical course in a small number of patients with non-Hodghn's lymphoma, it has been speculated that the lack of expression of adhesion molecules might result in an escape from immunos~rveillance.~~J~ Previously, we showed that one of the B-cell malignancies lacking CD1 l a expression, hairy cell leukemia (HCL), also expresses relatively low levels of CD54." This leukemia responds well to interferon-a (IFN-a) therapy but the underlying mechanism of this response remains unc1ear.l5J6 Several groups reported a lack of functional natural killer (NK) cells in HCL patients and poor susceptibility of the tumor cells to autologous and allogeneous LAK cells.17-19 We investigated whether CD54 and CDlla could be induced on HCL cells by culturing the cells in the presence of IFN-a or IL-4. Secondly, we tested whether induction of CDlla and CD54 on HCL cells was accompanied by enhanced susceptibility to LAK or CTL cytotoxicity. Finally, we monitored the in vivo expression of CDlla and CD54 on HCL cells in patients during IFN-a treatment.
CDlla and CD54 did not enhance susceptibility to either autologous or allogeneous LAK cells. However, induction of these adhesion molecules was accompanibd by enhanced susceptibility to lysis by cytotoxic T lymphocyte clones. This lysis could be reversed by the addition of anti-CDlla and anti-CD54 antibodies. Finally, we monitored the expression of CDlla and CD54 on HCL cells from patients during 1FN-a therapy. In one of four patients monitored, we obsenred rapid in vivo induction of CDlla and CD54 on the leukemic cells during IFN-a therapy. These studies provide a model for studying immunosurveillance in HCL. 8 1992 by The American Society of Hematology.
Previously, we showed that one of the B-cell malignancies lacking CD1 l a expression, hairy cell leukemia (HCL), also expresses relatively low levels of CD54." This leukemia responds well to interferon-a (IFN-a) therapy but the underlying mechanism of this response remains unc1ear.l5J6 Several groups reported a lack of functional natural killer (NK) cells in HCL patients and poor susceptibility of the tumor cells to autologous and allogeneous LAK cells. [17] [18] [19] We investigated whether CD54 and CDlla could be induced on HCL cells by culturing the cells in the presence of IFN-a or IL-4. Secondly, we tested whether induction of CDlla and CD54 on HCL cells was accompanied by enhanced susceptibility to LAK or CTL cytotoxicity. Finally, we monitored the in vivo expression of CDlla and CD54 on HCL cells in patients during IFN-a treatment.
MATERIALS AND METHODS

HCL cells.
After informed consent, cells were obtained from HCL patients who underwent splenectomy. Spleen cells were isolated by gentle mechanical disruption, washed, and mononuclear cells were isolated by Ficolhopaque (1.077 g/mL) density gradient centrifugation. If necessary, the cells were depleted of T lymphocytes by rosetting with 2-aminoethylisothiouronium bromide hydrobromide-treated sheep erythrocytes followed by Ficoll separation. Diagnosis was confirmed by histology of spleen and bone marrow, cytomorphology, cytochemical staining (tartrateresistant acid phosphatase positive), and immunophenotyping (reactivity with monoclonal antibodies [MoAbs] against CDllc, CD19, CD25, and expression of monotypic Igs). Cells were cryopreserved and thawed before use.
For the analysis of CDlla and CD54 expression in vivo during IFN-a therapy, we collected serial peripheral blood samples from selected patients with high numbers of circulating HCL cells who entered IFN-a therapy (3 x 1 8 U IFN-a; Schering Plough, Bloomfield, NJ; subcutaneously, three times a week). Mononuclear cells were isolated by Ficoll-Isopaque separation and used for immunofluorescence staining.
Peripheral blood was obtained after informed consent from healthy donors and from one HCL patient (case no. 3) during a nonleukemic stage of the disease. Light-density mononuclear cells were isolated by Ficoll-Isopaque centrifugation. LAK cells were generated by culturing these cells (0.5 x lo6 cells/mL) for 5 days in RPMI 1640 (GIBCO, Paisley, UK) supplemented with 10% human serum, antibiotics, and recombinant interleukin-2 LAK cells.
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(IL-2; 500 U/mL, a gift of Ortho, Raritan, NJ). Cultures were kept in a fully humidified, 5% C02 atmosphere at 37°C. LAK cells from 8 to 14 donors were tested against each HCL sample.
CTL clones. To assess susceptibility of the HCL cells to cytolytic T lymphocytes, we used two CTL clones (courtesy of Dr E.
Goulmy, Dept. of Immunohematology and Blood Bank, Leiden University Medical Center, Leiden, The Netherlands). One clone was directed against HLA-AI, the other againkt HLA-A2 antigen. Both clones were CD3+ and CD8+ as determined by reactivitywith the MoAbs Leu4 and Leu2a (Becton Dickinson, Mountain View, CA).
Culture conditions. HCL cells (4 x lo6) were cultured for 4 days in RPMI 1640 supplemented with 10% fetal calf serum (Hycldne, hgan, UT). IFN-a 2b (1, OOO U/mL; Schering Plough) or IL-4 (50 ng/mL; a kind gift of Dr P.P. Trotta, Schering Plough Research) was added to selected cultures. After 4 days, the cells were wiished and used for immunophenotyping and cell-mediated lysis experiments.
Immunofluorescence. Cells (0.5 x 106) were preincubated (30 minutes at 4°C) with 5% rabbit serum to prevent nonspecific 
RESULTS
Zmmunophenotype of HCL cells. Spleen cells of six HCL patients were analyzed for reactivity with several MoAbs. All HCL suspensions were positive for CDllc (>SO%), CD19 (> 80%), and one isotype of Ig light chain and negative for CD3 ( < 5%).
The effect of incubation with medium alone, IFN-a, or IL-4 was tested on the expression of several surface molecules by splenic HCL cells of six patients (Figs 1 and 2 ). CDlla expression, being absent on uncultured cells, was induced by IFN-a or IL-4. Culture in medium alone did not significantly enhance CDlla expression. CD18 expression (the common p chain of CDlla, CDllb, and CDllc) was slightly enhanced on cells cultured with IL-4. CDllb and CDllc expression was not altered by culturing under any of the conditions. CD54 expression was induced on all cultured cells irrespectively of the addition of cytokines to the culture medium. CD23, the low-affinity receptor for IgE, was induced by IL-4 (data not shown). CD25 expression was not altered by any of the .
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culture conditions. HLA-DR expression was enhanced by culturing thc cells in IFN-a or IL-4. HLA class I expression (constituting the epitope to be recognized by the CTL clones) was not altered under any of the culture conditions. As a control, expression of CD3 was analyzed. In all cases, the percentage of T cells remained low (<5%) after culture.
Because many experiments were performed with cryoprescrved cells, we studied whether C D l l a and CD54 expression was affected by freezethawing. Cells that were induced to express CDlla and CD54 by culturing for 4 days with IL-4 were analyzed either directly or after one freeze-thaw cycle. No difference was observed between these samples (data not shown).
Because the induction of CD54 was independent of the addition of cytokines, we cultured cells with low fetal calf serum (FCS), without FCS, or with autologous serum. None of these combinations gave different results from cultures with 10% FCS and we were thereforc not able to identify the CD54-inducing agent (data not shown).
Peripheral blood mononuclear cells were obtained from four selected patients with high numbers of circulating HCL cells before and after the start of IFN-a therapy (3 x lo6 U, subcutaneously, thrcc times a week). The expression of CDlla and CD54 on HCL cells was monitored using two-color fluorescence-activated cell sorter (FACS) analysis. HCL cells were identified by staining with phycoerythrin-conjugated anti-
Con~ol ~p e r i m~~t s .
In vivo induction of CDlla and CD54.
isotype light chain (A or K) antiserum. Expression of adhesion molecules on the HCL cells was monitored by simultaneous staining with FITC-labeled anti-CDlla or anti-CD54 antibodies. In one of the patients, a clear induction was observed of both CD54 and CDlla within 24 hours and 2 weeks after the start of IFN-a, respectively (Fig  3) . In the other three patients, no change was observed in the expression of either CD54 or CDlla during the interval of observation (0 to 14 days after the start of IFN-a therapy, data not shown).
HCL cells were cultured under various conditions and used as target for autologous and allogeneous LAIC cells. The cytolytic potential of the LAK cells was monitored by incubation with the LAK-sensitive cell lines K562 and HL-60. As shown in Table 1 , the lack of susceptibility to LAK activity was not altered by incubation of the HCL cells with IFN-a or IL-4. LAK cells that were generated from peripheral blood of HCL patient no. 3 during a hematologic remission proved to be poor effectors both against Ks62 (38% lysis) and against autologous splenic tumor cells (l%, 0%, 395, and 2% lysis of autologous spleen cells that were either not cultured or cultured in medium, IFN-a, and IL-4, respectively).
We used two CTL clones to test the susceptibility of the HCL cells to CTL cytotoxicity. One clone was directed against HLA-Al, the other against the HLA-A2 antigen. Uncultured HCL cells were poorly lysed by the CTL clones (mean lysis,
Lysis by U K cells.
Lysis by cytotoxic T lymphocytes. 
Values are percent lysis by allogeneous LAK cells (mean 2 SD). n is *Control for cytolytic potential of effector cells: K562, NK-and the number of LAK donors tested.
LAK-sensitive; HL-60, NK-insensitive, LAK-sensitive.
26% k 11%) despite strong expression of the relevant HLA molecule (Table 2 and Fig 2) . However, incubation of these cells for 4 days with medium alone, IL-4, or IFN-a resulted in a significant increase of lysis by the CTL clones to 56% k 28%, 62% 2 21%, and 54% 2 21%, respectively (at an effector:target ratio of 10:l). The expression of HLA class I (serving as the epitope to be recognized by the CTLs) did not alter under any of the culture conditions (Fig 2) . *The anti-HLA-A1 CTL clone was used against HCL-3 (HLA-AI) and the anti-HLA-A2 clone against HCL-1 and HCL-2 (both HLA-A1/A2).
Lysis a u l d be abrogated by incubation of the target cells with anti-CDlla and anti-CD54 antibody, either alone or in combination (Table 3) .
Correlation between cell-mediated lysis and expression of CDllalCD54. Because both the expression of CDlla/ CDS4 and susceptibility to lysis by CTLs were inducible on HCL cells, we calculated whether there was a correlation between the expression of these adhesion molecules and the susceptibility to lysis. Scatter plots were prepared from paired data from three patients (not shown). A positive correlation was observed between the expression of CD1 l a and susceptibility to lysis by CTLs (r = .75, 12 paired values) and between the expressiofi of CD54 and susceptibility to lysis by CTLs (r = .71,12 paired values).
DISCUSSION
In this report, we show that HCL cells, in addition to resistance to lysis by LAK cells, are poor targets fQf cytotoxic T cells. We tested whether the absence of the adhesion molecules CDlla and CD54 might be the cause of this resistance. First, we showed that expression of these molecules is inducible on HCL cells. IL-4 and IFN-a induced the expression of CDlla, whereas incubation of the cells in medium alone was sufficient to induce expression of CD54. We next tested the susceptibility of HCL cells to LAK cell and CTL cytotoxicity before and after induction of CDlla and CD54. As effector cells, allogeneous LAK cells from 14 different healthy donors, autologous LAK cells from one HCL patient, and two cytotoxic T-cell lines directed against the HLA-A1 and HLA-M antigens were used. Induction of CDlla and CD54 did not induce susceptibility to lysis by LAK cells, but HCL cells that were cultured under CDlla-and CD54-inducing conditions did become sensitive to lysis by the CTLs. Preincqbation of the target HCL cells with anti-CDlla and anti-CD54, either alone or in combination, inhibited the lysis by CTLs, suggesting that induction of both adhesion molecules was important for the observed CTL-mediated lysis. However, because cells that were cultured in medium alone showed only minimal induction of CDlla, whereas strong induction of CD54 was seen, and these cells became susceptible to lysis by CTLs, induction of CD54 may be causative for the observed induction of susceptibility to lysis by CTLs. 'HCL-3 cells were preincubated (30 minutes) with anti-CD1 l a (aL) or anti-CD54 (RRI/I.I.I) antibody, washed, and used as target for lysis by the anti-HLA-AI CTL clone (effect0r:target = 2O:l).
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These results suggest that interaction of tuinor cells with T cells (not necessarily cytotoxic) may be impaired in HCL, possibly beqause the HCL cells lack relevant adhesion molecules. The observation that there are few infiltrating T cells in HCL spleensm may support this theory. The induction of CDlla and CD54 on HCL cells in vivo in one of four patients monitored during IFN-a therapy shows that the same mechanism may be relevant to the therapeutic effect of IF"-a. The assumption that cytotoxic T cells are involved in the elimination of HCL cells during @ " a therapy could be tested by determination of the frequency of tumor-specific, autoreactive T cells before and after IFN-a therapy.
